专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

21. 发明公开

KR1020100002207A ＣＤ９―특이적인 인간항체 有权
标题翻译： CD9特异性人体抗体
公开(公告)号：KR1020100002207A
公开(公告)日：2010-01-06
申请号：KR1020090057316
申请日：2009-06-25
申请人： 한국생명공학연구원 , 성균관대학교산학협력단
发明人： 박영우 , 최소영 , 박지현 , 유정 , 송은정 , 김성섭 , 장명희 , 박미주 , 이제호 , 황재령
IPC分类号： C07K16/28 , C07K16/00 , A61P35/00 , A61K39/395
CPC分类号： C07K16/2896 , C07K2317/21 , C07K2317/34 , C07K2317/565 , C07K2317/73 , C07K2317/76
摘要： PURPOSE: A CD9-specific human antibody is provided to suppress cancer cell line and prevent and treat CD9 overexpressed cancer. CONSTITUTION: A CD9-specific human antibody contains a heavy chain having variable region with HCDR and light chain having variable region with LCDR. A method for preparing the CD9-specific human antibody comprises: a step of preparing an expression vector having a gene encoding a polypeptide corresponding to a fragment having immunological activation of light chain and heavy chain; a step of introducing the expression vector to a host cell to prepare a transformant; a step of culturing the transformant; and a step of isolating antibodies from the culture medium. A pharmaceutical composition for preventing and treating gastric cancer or ovarian cancer contains the CD9-specific human antibody.
摘要翻译：目的：提供CD9特异性人抗体来抑制癌细胞系，并预防和治疗CD9过表达的癌症。构成：CD9特异性人抗体含有具有HCDR可变区的重链和具有LCDR的可变区的轻链。制备CD9特异性人抗体的方法包括：制备具有编码对应于具有轻链和重链的免疫激活的片段的多肽的基因的表达载体的步骤; 将表达载体导入宿主细胞以制备转化体的步骤; 培养转化体的一个步骤; 以及从培养基中分离抗体的步骤。用于预防和治疗胃癌或卵巢癌的药物组合物含有CD9特异性人抗体。

22. 发明授权

KR101618767B1 외래단백질을 고효율로 생산하는 리더서열 有权
标题翻译：高表达异源蛋白质需要有效的前导序列
公开(公告)号：KR101618767B1
公开(公告)日：2016-05-09
申请号：KR1020080086232
申请日：2008-09-02
申请人： 한국생명공학연구원
发明人： 박영우 , 전재원 , 박지현 , 정준구
IPC分类号： C07K14/00 , C07K7/00
摘要： 본발명은외래단백질을고효율로생산하는리더서열및 그를이용한외래단백질의고효율생산방법에관한것으로, 구체적으로는외래단백질을고효율로발현하게하는 75종의리더서열과상기리더서열을포함하는발현벡터, 상기발현벡터에의해형질감염된세포주및 상기세포주를이용한재조합외래단백질의생산방법및 외래단백질을고발현시키기위한최적의리더서열을선별할수 있는스크리닝방법에관한것이다. 본발명의리더서열과벡터및 세포주에의해고역가로대량생산된외래단백질은여러가지바이오의약품생산에유용하게사용될수 있다.

23. 发明公开

KR1020120044075A 남세균 유래 내염성 ＳｙＤＢＳＰ 유전자 및 이의 용도 有权
标题翻译：耐盐性SYDBSP基因从SYNECHOCYSTIS及其用途
公开(公告)号：KR1020120044075A
公开(公告)日：2012-05-07
申请号：KR1020100105471
申请日：2010-10-27
申请人： 한국생명공학연구원
发明人： 유장렬 , 김석원 , 김종현 , 민성란 , 정원중 , 안명숙 , 박영민 , 오명진 , 박지현
IPC分类号： A01H5/00 , C07K14/195 , C12N15/31 , C12N15/82
CPC分类号： C07K14/405 , C07K14/195 , C12N15/8273 , C12Q1/6895
摘要： PURPOSE: A gene encoding Synechocystis PCC 6906-deribed SyDBSP protein is provided to enhance salt resistance in a plant and use a transgenic plant. CONSTITUTION: A Synechocystis PCC 6906-derived SyDBSP(Synechocystis putative DNA binding stress protein) has an amino acid sequence of sequence number 2. A gene encoding SyDBSP protein contains a base sequence of sequence number 1. A method for enhancing salt resistance in the plant comprises a step of transforming a plant cell with a vector containing SyDBSP gene and overexpressing the SyDBSP gene. A composition for enhancing salt tolerance in the plant contains the SyDBSP gene.
摘要翻译：目的：提供编码集胞藻PCC 6906的SyDBSP蛋白的基因，以增强植物的耐盐性，并使用转基因植物。构成：集胞藻PCC 6906衍生的SyDBSP（集胞藻推定的DNA结合应激蛋白）具有序列号2的氨基酸序列。编码SyDBSP蛋白的基因含有序列号1的碱基序列。提高植物耐盐性的方法包括用含有SyDBSP基因并过量表达SyDBSP基因的载体转化植物细胞的步骤。用于提高植物耐盐性的组合物含有SyDBSP基因。

24. 发明授权

KR101004363B1 자가 면역 질환 예방 및 치료용 ＴＮＦ－α와 ＩＬ－２１ 이중 길항제 有权
标题翻译：用于预防和治疗自身免疫性疾病的TNF-α和IL-21联合拮抗剂
公开(公告)号：KR101004363B1
公开(公告)日：2010-12-28
申请号：KR1020100024700
申请日：2010-03-19
申请人： 한국생명공학연구원 , 가톨릭대학교 산학협력단
发明人： 박영우 , 조기원 , 유석호 , 유정 , 윤선하 , 박지현 , 송은정 , 이종호 , 서민지 , 조선정 , 조미라 , 김호연 , 박미경 , 오혜좌 , 박진실 , 우윤주
IPC分类号： C07K19/00 , C12N15/62 , C12N15/63 , A61P37/00
CPC分类号： C07K14/7151 , C07K14/7155 , C07K2319/00
摘要： PURPOSE: A TNFR2-IL21R fusion protein as a double antagonist to TNF-alpha and IL-21 is provided to reduce inflammatory cytokine secretion and to increase anti-inflammatory cytokine secretion. CONSTITUTION: A composition for preventing and treating autoimmune disease contains a fusion protein having a fragment with extracellular region of TNFR2(Tumor necrosis factor receptor type 2) or TNFR2 and a fragment with extracellular region of IL21R(Interleukin-21 receptor) protein or IL21R as an active ingredient. The fusion protein has an amino acid sequence of sequence number 1.
摘要翻译：目的：提供TNFR2-IL21R融合蛋白作为TNF-α和IL-21的双重拮抗剂，以减少炎症细胞因子分泌和增加抗炎细胞因子分泌。构成：用于预防和治疗自身免疫疾病的组合物含有具有TNFR2细胞外区域（2型肿瘤坏死因子受体）或TNFR2的片段和IL21R（白细胞介素-21受体）蛋白或IL21R的细胞外区域的片段的融合蛋白，作为活性成分。融合蛋白具有序列号1的氨基酸序列。

25. 发明公开

KR1020100042432A ＴＭＰＲＳＳ４―특이적인 인간항체 有权
标题翻译： TMPRSS4特异性人体抗体
公开(公告)号：KR1020100042432A
公开(公告)日：2010-04-26
申请号：KR1020080101575
申请日：2008-10-16
申请人： 한국생명공학연구원
发明人： 박영우 , 최소영 , 장영순 , 박지현 , 송은정 , 유정 , 손명호 , 전재원 , 정준구 , 김성섭 , 장명희
IPC分类号： C07K16/18 , C07K16/00 , C12Q1/68
CPC分类号： C07K16/40 , A61K2039/505 , C07K2317/21 , C07K2317/52 , C07K2317/622 , C07K2317/73 , C07K2319/00 , C12N9/6424 , C07K2317/76 , C12N15/63
摘要： PURPOSE: A TMPRSS4(Transmembrane protease, serine 4)-specific human antibody is provided to use in cancer diagnosis, classification, imaging, treatment and prognosis determination. CONSTITUTION: A human antibody which is specific to TMPRSS4 contains heavy chain with heavy chain variable region(VH) or fraction thereof; and light chain containing the light chain variable region(VL) or fragment thereof. The heavy chain of the heavy chain variable region contains heavy chain complementarity determining region(HCDR 1) of amino acid selected from sequence numbers 7-18, HCDR 2 of amino acid selected from sequence numbers 19-31, or HCDR3 of amino acid selected from sequence numbers 32-44. A pharmaceutical composition for preventing and treating cancer in which TMPRSS4 is overexpressed contains TMPRSS4-specific human antibody.
摘要翻译：目的：提供TMPRSS4（跨膜蛋白酶，丝氨酸4）特异性人抗体用于癌症诊断，分类，成像，治疗和预后测定。构成：对TMPRSS4特异性的人抗体含有重链可变区（VH）或其部分的重链; 和含有轻链可变区（VL）或其片段的轻链。重链可变区的重链含有选自序列号7-18的氨基酸的重链互补决定区（HCDR 1），选自序列号19-31的氨基酸的HCDR 2或选自SEQ ID NO：序列号32-44。用于预防和治疗其中TMPRSS4过表达的癌症的药物组合物含有TMPRSS4特异性人抗体。

26. 发明授权

KR100910962B1 ＥＮＯ１―특이적인 인간항체 失效
标题翻译： ENO1特异性人体抗体
公开(公告)号：KR100910962B1
公开(公告)日：2009-08-05
申请号：KR1020080092736
申请日：2008-09-22
申请人： 한국생명공학연구원
发明人： 박영우 , 허광래 , 최소영 , 박지현 , 송은정 , 유정 , 손명호 , 김성섭 , 장명희 , 김동진
IPC分类号： C07K16/18 , C07K16/00
CPC分类号： C07K16/40 , C07K2317/21 , C07K2317/565 , C07K2317/622
摘要： A human antibody comprising a complementarity determining region (CDR) and framework region (FR) which are induced from a human is provided to use for cancer diagnosis, disease classification, imaging, treatment, and prognosis determination. A human antibody which is specific to ENO1 comprises: a heavy chain CDR (HCDR) 1 which is a polypeptide among sequence numbers 7-12; a polypeptide HCD 2 among the sequence numbers 13-18; a heavy chain having various heavy site (VH) comprising a HCD 3 which is polypeptide among sequence numbers 19-24 and its immunologically active fragment; a light chain CDR 1 which is a polypeptide among sequence numbers 31-36; and a polypeptide LCDR 2 among sequence numbers 37-42.
摘要翻译：提供了包含由人诱导的互补决定区（CDR）和框架区（FR）的人抗体用于癌症诊断，疾病分类，成像，治疗和预后测定。对ENO1特异性的人抗体包括：序列号7-12中的多肽的重链CDR（HCDR）1; 序列号13-18中的多肽HCD 2; 具有各种重位点（VH）的重链，其包含序列号19-24中的多肽的HCD 3及其免疫活性片段; 序列号31-36中多肽的轻链CDR1; 和序列号37-42中的多肽LCDR 2。

27. 发明授权

KR101521434B1 대장균 유래 ＴＰＳＰ 유전자를 이용한 고온 스트레스 내성 형질전환 식물체의 제조방법 및 그에 따른 식물체 有权
标题翻译：使用来自大肠杆菌的TPSP基因及其植物生产具有耐高温胁迫性的转基因植物的方法
公开(公告)号：KR101521434B1
公开(公告)日：2015-05-20
申请号：KR1020120108982
申请日：2012-09-28
申请人： 한국생명공학연구원
发明人： 유장렬 , 민성란 , 유재일 , 박지현 , 오광훈 , 정원중
IPC分类号： A01H5/00 , C12N15/82 , C12N15/31
摘要： 본발명은대장균유래 TPSP (trehalose-6-phosphate synthase/phosphatase fusion) 유전자를포함하는재조합벡터로식물세포를형질전환하는단계를포함하는생육저해현상이나형태적변형없이고온스트레스에대한내성이증진된형질전환식물체의제조방법및 상기제조방법에의해제조된생육저해현상이나형태적변형없이고온스트레스에대한내성이증가된형질전환식물체에관한것으로, 본발명의 TPSP 과발현형질전환식물체는고온스트레스환경에서생산성향상과수확량증대에크게기여할수 있을것으로기대된다.

28. 发明公开

KR1020120100027A 엔도사이토시스 모티프 및 단백질 도입 도메인을 포함하는 암 예방 또는 치료용 약학적 조성물 审中-实审
标题翻译：用于预防或治疗包含内源性MOTIF和蛋白质转染域的癌症的药物组合物
公开(公告)号：KR1020120100027A
公开(公告)日：2012-09-12
申请号：KR1020110018628
申请日：2011-03-02
申请人： 한국생명공학연구원
发明人： 박영우 , 조기원 , 조규원 , 박지현 , 현순실 , 박윤정
IPC分类号： C07K7/08 , C07K14/475 , A61K38/00 , A61K38/10 , A61K38/18
CPC分类号： C07K7/08 , A61K38/00 , C07K14/00 , C07K14/4753 , C07K2319/10 , A61K38/10 , A61K38/18
摘要： PURPOSE: A pharmaceutical composition for cancer prevention or treatment including endocytic motif and protein introduction domain is provided to specifically inhibit endocytosis of c-Met by polypeptide in order to effectively inhibits HGF/c-Met signal transmission path and inhibit transition, infiltration, vascularization and growth of cancer. CONSTITUTION: A pharmaceutical composition for cancer prevention or treatment includes endocytic motif which is represented as amino acid sequence having the sequence number 1(SEQ ID NO:1). The motif is imported inside cells by clathrin mediated endocytosis. The motif is c-Met, phosphorylated c-Met, or c-Met combined with HGF(hepatocyte growth factor). The motif inhibits self - phosphorylation of c-Met by HGF. The Pharmaceutical composition for preventing or treating cancers includes motif as an active ingredient. A fused polypeptide is endocytotic motif-C terminal represented by equation 1: N-terminal-protein transduction domain-amino acid sequence having the sequence number 1 or endocytic motif - protein transduction domain -C terminal represented by equation 2: N- terminal-amino acid sequence having the sequence number 1. The protein transduction domain is Tat of HIV(human immunodeficiency virus); VP22 of HSP(herpes simplex virus); Antp of pomace fly; Mph-1; Sim-2; R7; Pep-1; or Pep-2.
摘要翻译：目的：提供一种用于癌症预防或治疗的药物组合物，包括内吞基序和蛋白质引入结构域，以特异性抑制多肽对c-Met的内吞作用，以有效抑制HGF / c-Met信号传递途径并抑制转化，浸润，血管化和癌症的增长。构成：用于癌症预防或治疗的药物组合物包括表示为具有序列号1（SEQ ID NO：1）的氨基酸序列的内吞基序。该基序通过网格蛋白介导的内吞作用进入细胞内。该基序是c-Met，磷酸化c-Met或c-Met与HGF（肝细胞生长因子）组合。该基序抑制HGF自身磷酸化c-Met。用于预防或治疗癌症的药物组合物包括作为活性成分的基序。融合多肽是由等式1表示的内吞基序-C末端：具有序列号1的N末端蛋白转导结构域 - 氨基酸序列或由等式2表示的内吞基序 - 蛋白转导结构域-C末端：N-末端氨基具有序列号1的酸序列。蛋白转导结构域是HIV的Tat（人免疫缺陷病毒）; HSP（单纯疱疹病毒）VP22; 荞麦飞 MPH-1; SIM-2; R7; PEP-1; 或Pep-2。

29. 发明授权

KR101526307B1 항염증성 약학 조성물 有权
标题翻译：抗炎药物组成
公开(公告)号：KR101526307B1
公开(公告)日：2015-06-11
申请号：KR1020090006592
申请日：2009-01-28
申请人： 한국생명공학연구원
发明人： 박영우 , 전재원 , 정준구 , 최혜인 , 박지현 , 장영순
IPC分类号： A61K39/395 , A61P29/00
摘要： 본발명은항염증성약학조성물, 특히 CD93의수용성단편(sCD93)에대한특이적인항체를유효성분으로포함하는항염증성약학조성물을개시한다.

30. 发明公开

KR1020140042339A 대장균 유래 ＴＰＳＰ 유전자를 이용한 고온 스트레스 내성 형질전환 식물체의 제조방법 및 그에 따른 식물체 有权
标题翻译：用于生产具有耐高温胁迫的转基因植物的方法，该方法使用来自欧洲花椰菜的TPSP基因及其植物
公开(公告)号：KR1020140042339A
公开(公告)日：2014-04-07
申请号：KR1020120108982
申请日：2012-09-28
申请人： 한국생명공학연구원
发明人： 유장렬 , 민성란 , 유재일 , 박지현 , 오광훈 , 정원중
IPC分类号： A01H5/00 , C12N15/82 , C12N15/31
CPC分类号： C12N15/8271 , C07K14/245 , C12N15/8205 , C12N15/8216
摘要： The present invention relates to a method for producing a transgenic plant having resistance to high temperature stress without a growth and development inhibition phenomenon or morphological transformation comprising a step of transforming plant cells with a recombinant vector comprising a trehalose-6-phosphate synthase/phosphatase fusion (TPSP) gene derived from Escherichia Coli and a transgenic plant having enhanced resistance to high temperature stress without a growth and development inhibition phenomenon or morphological transformation manufactured by the same method. A TPSP overexpressing transgenic plant of the present invention is expected to greatly contribute to improve productivity and yield under high temperature stress environment.
摘要翻译：本发明涉及一种具有抗高温胁迫而没有生长发育抑制现象或形态转化的转基因植物的方法，其包括用包含海藻糖-6-磷酸合酶/磷酸酶融合物的重组载体转化植物细胞的步骤（TPSP）基因和具有增强的抗高温胁迫抗性的转基因植物，而没有生长发育抑制现象或通过相同方法制造的形态转化。预期本发明的过度表达转基因植物的TPSP将有助于在高温胁迫环境下提高生产率和产量。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式